Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06550102 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Drug Response Profiling (DRP) Registry Zurich for Hematological Malignancies

Study acronym: DRP_ZH
StatusRecruiting
PhaseNot specified
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Secondary endpoints: details revised at 1 of 2 entries
    • Study description expanded, about 53 words
    v2
  2. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This study is a prospective, non-randomized feasibility study of drug response profiling (DRP) in pediatric blood cancers. Primary cancer cells are isolated from patients and screened ex vivo at single-cell resolution using automated fluorescence microscopy. Drug sensitivity fingerprints are integrated with genetic annotations to inform the treating physician about personalized treatment options. The study aims to determine the practicability of real-time drug response profiling and its actionability in identifying patient-specific cancer dependencies in refractory disease settings.
Trial Details
NCT Number NCT06550102
Lead Sponsor University Children's Hospital, Zurich
Conditions
(from sponsor)		 Hematological Malignancies
Related terms Hematologic Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma
Enrollment 1,000 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov